Medical Condition News RSS Feed - Medical Condition News

Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation

Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation

Digoxin, a drug commonly used to treat heart conditions, was associated with a 71 percent higher risk of death and a 63 percent higher risk of hospitalization among adults with diagnosed atrial fibrillation and no evidence of heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Arrhythmia and Electrophysiology. [More]
Scientists identify four new genes associated with severe food allergy

Scientists identify four new genes associated with severe food allergy

Scientists have identified four new genes associated with the severe food allergy eosinophilic esophagitis (EoE). Because the genes appear to have roles in other allergic diseases and in inflammation, the findings may point toward potential new treatments for EoE. [More]
2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only medication approved in Canada with a specific IPF indication and is approved for mild to moderate IPF in adults. [More]
Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Research published today found that the investigational drug patiromer decreased high potassium levels and maintained normal potassium levels in patients with chronic kidney disease. The results of a multicenter trial appear in the New England Journal of Medicine. [More]
EDDA Technology to introduce IQQA-BodyImaging, cloud-based OnDemand service at RSNA 2014

EDDA Technology to introduce IQQA-BodyImaging, cloud-based OnDemand service at RSNA 2014

EDDA Technology, a global leading provider in advanced real-time interactive quantitative imaging solutions, announced today that the company has received FDA clearance on IQQA-BodyImaging. [More]
Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
TSRI study shows how mutations in Tmie gene can cause deafness from birth

TSRI study shows how mutations in Tmie gene can cause deafness from birth

Scientists at The Scripps Research Institute have discovered how one gene is essential to hearing, uncovering a cause of deafness and suggesting new avenues for therapies. [More]
Month-long residential program helps young adults stay drug-free

Month-long residential program helps young adults stay drug-free

Residential treatment may be an appropriate first-line option for young adults who are dependent on opioid drugs - including prescription painkillers and heroin - and may result in higher levels of abstinence than does the outpatient treatment that is currently the standard of care. [More]
Researchers discover new method to deliver drugs into aggressive tumors

Researchers discover new method to deliver drugs into aggressive tumors

A multi-disciplinary team of Yale Cancer Center researchers has discovered a promising new method for delivering drugs into aggressive tumors by exploiting a unique feature of tumors themselves. [More]
MD Anderson study sheds light on little-known protein complex

MD Anderson study sheds light on little-known protein complex

A study at The University of Texas MD Anderson Cancer Center led by Mong-Hong Lee, Ph.D., a professor of molecular and cellular oncology, has demonstrated the significance of CSN6 in regulating Myc which may very well open up a new pathway for treating and killing tumors. [More]
Lombard Medical presents positive data from PYTHAGORAS PMA trial of Aorfix at VEITHsymposium

Lombard Medical presents positive data from PYTHAGORAS PMA trial of Aorfix at VEITHsymposium

Lombard Medical, Inc., a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today presented efficacy and safety data from the two-year follow up of the U.S. PYTHAGORAS pre-marketing approval (PMA) trial of Aorfix, the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees. [More]
New treatment for Marfan syndrome works as well as beta blockers

New treatment for Marfan syndrome works as well as beta blockers

A new treatment for Marfan syndrome, a rare genetic disease that can lead to heart problems, works as well as the currently recommended medical therapy, beta blockers, according to an article in the New England Journal of Medicine. [More]
Kidney disease patients can benefit from simple and structured exercise

Kidney disease patients can benefit from simple and structured exercise

Simple yet structured exercise can significantly improve kidney disease patients' quality of life as well as decrease their pain, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). [More]
Obese people experience silent cardiac damage that fuels risk for heart failure

Obese people experience silent cardiac damage that fuels risk for heart failure

Using an ultrasensitive blood test to detect the presence of a protein that heralds heart muscle injury, researchers from Johns Hopkins and elsewhere have found that obese people without overt heart disease experience silent cardiac damage that fuels their risk for heart failure down the road. [More]
Self-acupressure may be effective for treating constipation

Self-acupressure may be effective for treating constipation

About 19 percent of North Americans suffer from constipation, with the digestive condition being more common among women, non-whites, people older than 60, those who are not physically active and the poor. [More]
Snus consumption in Norway is highest among young people

Snus consumption in Norway is highest among young people

The increase in Scandinavian snus consumption in Norway is highest among young people, according to a new report from the Norwegian Institute of Public Health. [More]

Alliance for Balanced Pain Management established to support appropriate access to pain management

A diverse collective of health care advocacy groups, patient organizations, industry representatives and other stakeholders today announced they have established the Alliance for Balanced Pain Management (AfBPM) to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to reduce abuse. [More]
Children of women who work full time get fewer hours of sleep, have higher BMIs

Children of women who work full time get fewer hours of sleep, have higher BMIs

The majority of preschoolers may not be getting the amount of sleep they need each night, placing them at higher risk of being overweight or obese within a year, according to a new study. [More]
New course underlines the importance of early detection of lung cancer

New course underlines the importance of early detection of lung cancer

In Japan, 40 percent of lung cancer cases are detected on early stages and treated with a high probability of remission; in the US 20 percent of cases have that possibility, while in Mexico, in the National Cancer Institute (INCan), only 1.2 percent of patients are diagnosed at an early stage. [More]
No added benefit proven for empagliflozin in type 2 diabetes

No added benefit proven for empagliflozin in type 2 diabetes

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. [More]